Cargando…
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model
OBJECTIVES: Dopamine-replacement utilizing L-DOPA is still the mainstay treatment for Parkinson’s disease (PD), but often leads to development of L-DOPA-induced dyskinesia (LID), which can be as debilitating as the motor deficits. There is currently no satisfactory pharmacological adjunct therapy. T...
Autores principales: | Bartlett, Mitchell J., So, Lisa Y., Szabò, Lajos, Skinner, David P., Parent, Kate L., Heien, Michael L., Vanderah, Todd W., Polt, Robin, Sherman, Scott J., Falk, Torsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066739/ https://www.ncbi.nlm.nih.gov/pubmed/32164786 http://dx.doi.org/10.1186/s13104-020-04994-7 |
Ejemplares similares
-
The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia
por: Bartlett, Mitchell J., et al.
Publicado: (2020) -
Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia
por: Bartlett, Mitchell J., et al.
Publicado: (2020) -
Opioid system in L-DOPA-induced dyskinesia
por: Pan, Jing, et al.
Publicado: (2017) -
Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias
por: Sherman, Scott J., et al.
Publicado: (2016) -
Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
por: Wang, Qiang, et al.
Publicado: (2016)